Unlike KIT/PDGFRA mutation-driven GIST, WT GIST are often not responsive to targeted therapy with the first-generation tyrosine kinase inhibitor (TKI) imatinib, and only limited clinical benefit has been observed with the newer-generation TKIs sunitinib and regorafenib9–11. Here, PDGFRA is linked to gastrointestinal stromal tumor.